2.3M XNAS Volume
XNAS 17 Mar, 2025 5:30 PM (EDT)
Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|
William P. Forbes | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 187,110 | 187,110 | - | - | Restricted Stock Units | |
William P. Forbes | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 374,220 | 374,220 | - | - | Employee Stock Option (Right to Buy) | |
Craig A. Collard | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 1,113,240 | 1,113,240 | - | - | Employee Stock Option (Right to Buy) | |
Craig A. Collard | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 556,620 | 556,620 | - | - | Restricted Stock Units | |
Ira Duarte | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 187,110 | 187,110 | - | - | Restricted Stock Units | |
Ira Duarte | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 374,220 | 374,220 | - | - | Employee Stock Option (Right to Buy) | |
Craig A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 17,950 | 83,770 (0%) | 0% | 0 | Common Stock | |
Craig A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 35,900 | 35,900 | - | - | Stock Option (Right to Buy) | |
Christian Waage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 35,900 | 35,900 | - | - | Stock Option (Right to Buy) | |
Christian Waage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 17,950 | 84,130 (0%) | 0% | 0 | Common Stock | |
Michael Kaseta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 35,900 | 35,900 | - | - | Stock Option (Right to Buy) | |
Michael Kaseta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 17,950 | 55,829 (0%) | 0% | 0 | Common Stock | |
Susan Rodriguez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 17,950 | 87,180 (0%) | 0% | 0 | Common Stock | |
Susan Rodriguez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 35,900 | 35,900 | - | - | Stock Option (Right to Buy) | |
Sharmila Dissanaike | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 35,900 | 35,900 | - | - | Stock Option (Right to Buy) | |
Sharmila Dissanaike | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 17,950 | 87,180 (0%) | 0% | 0 | Common Stock | |
Adam Morgan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 17,950 | 69,777 (0%) | 0% | 0 | Common Stock | |
Adam Morgan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 35,900 | 35,900 | - | - | Stock Option (Right to Buy) | |
Craig A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 35,900 | 35,900 | - | - | Stock Option (Right to Buy) | |
Craig A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 17,950 | 83,770 (0%) | 0% | 0 | Common Stock | |
Christian Waage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 17,950 | 84,130 (0%) | 0% | 0 | Common Stock | |
Christian Waage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 35,900 | 35,900 | - | - | Stock Option (Right to Buy) | |
Michael Kaseta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 35,900 | 35,900 | - | - | Stock Option (Right to Buy) | |
Michael Kaseta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 17,950 | 55,829 (0%) | 0% | 0 | Common Stock | |
Susan Rodriguez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 17,950 | 87,180 (0%) | 0% | 0 | Common Stock | |
Susan Rodriguez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 35,900 | 35,900 | - | - | Stock Option (Right to Buy) | |
Sharmila Dissanaike | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 17,950 | 87,180 (0%) | 0% | 0 | Common Stock | |
Sharmila Dissanaike | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 35,900 | 35,900 | - | - | Stock Option (Right to Buy) | |
Adam Morgan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 35,900 | 35,900 | - | - | Stock Option (Right to Buy) | |
Adam Morgan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 17,950 | 69,777 (0%) | 0% | 0 | Common Stock | |
William P. Forbes | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2025 | 3,874 | 106,997 (0%) | 0% | - | Common Stock | |
William P. Forbes | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2025 | 3,874 | 46,492 | - | - | Restricted Stock Units | |
Craig A. Collard | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2025 | 13,797 | 314,867 (0%) | 0% | - | Common Stock | |
Craig A. Collard | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2025 | 13,797 | 165,562 | - | - | Restricted Stock Units | |
Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2025 | 3,874 | 120,580 (0%) | 0% | - | Common Stock | |
Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2025 | 3,874 | 46,492 | - | - | Restricted Stock Units | |
Michael Kaseta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Nov 2024 | 227,272 | 227,272 | - | - | Stock Option (Right to Buy) | |
Michael Kaseta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Nov 2024 | 37,879 | 37,879 (0%) | 0% | - | Common Stock | |
William P. Forbes | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2024 | 3,874 | 50,366 | - | - | Restricted Stock Units | |
William P. Forbes | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2024 | 3,874 | 103,123 (0%) | 0% | - | Common Stock | |
Craig A. Collard | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2024 | 13,797 | 290,387 (0%) | 0% | - | Common Stock | |
Craig A. Collard | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2024 | 13,797 | 179,359 | - | - | Restricted Stock Units | |
Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2024 | 3,874 | 50,366 | - | - | Restricted Stock Units | |
Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2024 | 3,874 | 108,001 (0%) | 0% | - | Common Stock | |
William P. Forbes | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2024 | 3,875 | 99,249 (0%) | 0% | - | Common Stock | |
William P. Forbes | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2024 | 3,875 | 54,240 | - | - | Restricted Stock Units | |
Craig A. Collard | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2024 | 13,797 | 193,156 | - | - | Restricted Stock Units | |
Craig A. Collard | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2024 | 13,797 | 276,590 (0%) | 0% | - | Common Stock | |
Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2024 | 3,875 | 104,127 (0%) | 0% | - | Common Stock | |
Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2024 | 3,875 | 54,240 | - | - | Restricted Stock Units | |
Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 12,500 | 100,252 (0%) | 0% | - | Common Stock | |
Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 12,500 | 37,500 | - | - | Restricted Stock Units | |
William P. Forbes | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jun 2024 | 12,500 | 37,500 | - | - | Restricted Stock Units | |
William P. Forbes | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jun 2024 | 12,500 | 95,374 (0%) | 0% | - | Common Stock | |
William P. Forbes | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2024 | 3,874 | 58,115 | - | - | Restricted Stock Units | |
William P. Forbes | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2024 | 3,874 | 82,874 (0%) | 0% | - | Common Stock | |
Craig A. Collard | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2024 | 13,797 | 262,793 (0%) | 0% | - | Common Stock | |
Craig A. Collard | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2024 | 13,797 | 206,953 | - | - | Restricted Stock Units | |
Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2024 | 3,874 | 88,874 (0%) | 0% | - | Common Stock | |
Ira Duarte | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.64 per share. | 19 Apr 2024 | 1,122 | 87,752 (0%) | 0% | 2.6 | 2,962 | Common Stock |
Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2024 | 3,874 | 58,115 | - | - | Restricted Stock Units | |
Craig A. Collard | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2024 | 62,500 | 248,996 (0%) | 0% | - | Common Stock | |
Craig A. Collard | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2024 | 62,500 | 187,500 | - | - | Restricted Stock Units | |
Ira Duarte | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 371,935 | 371,935 | - | - | Employee Stock Option (Right to Buy) | |
Dissanaike Sharmila | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 83,685 | 83,685 | - | - | Stock Option (Right to Buy) | |
Duarte Ira | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 61,989 | 61,989 | - | - | Restricted Stock Units | |
Susan Rodriguez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 83,685 | 83,685 | - | - | Stock Option (Right to Buy) | |
Craig Johnson A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 13,948 | 65,820 (0%) | 0% | 0 | Common Stock | |
Waage Christian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 13,948 | 66,180 (0%) | 0% | 0 | Common Stock | |
Lisa Peraza | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 41,078 | 41,078 | - | - | Employee Stock Option (Right to Buy) | |
Christian Waage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 83,685 | 83,685 | - | - | Stock Option (Right to Buy) | |
P. Forbes William | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 61,989 | 61,989 | - | - | Restricted Stock Units | |
Craig A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 83,685 | 83,685 | - | - | Stock Option (Right to Buy) | |
Craig A. Collard | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 220,750 | 220,750 | - | - | Restricted Stock Units | |
A. Craig Collard | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 1,324,502 | 1,324,502 | - | - | Employee Stock Option (Right to Buy) | |
Rodriguez Susan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 13,948 | 69,230 (0%) | 0% | 0 | Common Stock | |
Dissanaike Sharmila | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 13,948 | 69,230 (0%) | 0% | 0 | Common Stock | |
Morgan Adam | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 83,685 | 83,685 | - | - | Stock Option (Right to Buy) | |
Peraza Lisa | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 6,846 | 6,846 | - | - | Restricted Stock Units | |
Forbes William P. | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 371,935 | 371,935 | - | - | Employee Stock Option (Right to Buy) | |
Adam Morgan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 13,948 | 51,827 (0%) | 0% | 0 | Common Stock | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 1,289 | 56,663 (0%) | 0% | - | Common Stock | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 552 | 55,374 (0%) | 0% | - | Common Stock | |
Peraza Lisa | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 1,289 | 6,675 | - | - | Restricted Stock Units | |
Peraza Lisa | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.15 per share. | 13 Jan 2024 | 756 | 55,907 (0%) | 0% | 2.1 | 1,625 | Common Stock |
Peraza Lisa | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 552 | 1,656 | - | - | Restricted Stock Units | |
Craig A. Collard | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.65 per share. | 22 Aug 2023 | 692 | 36,496 (0%) | 0% | 1.7 | 1,142 | Common Stock |
Adam Morgan | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 21 Jul 2023 | 1,162,891 | 1,162,891 | - | - | Pre-funded Warrants to Purchase Common Stock | |
Adam Morgan | Director | Purchase of securities on an exchange or from another person at price $ 1.37 per share. | 21 Jul 2023 | 2,486,744 | 6,986,744 (7%) | 2% | 1.4 | 3,406,839 | Common Stock, par value $0.01 per share |
Lisa Peraza | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2023 | 150,000 | 150,000 | - | - | Employee Stock Option (Right to Buy) | |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2023 | 4,564 | 35,766 (0%) | 0% | - | Common Stock | |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2023 | 4,564 | 23,372 | - | - | Restricted Stock Units | |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2023 | 1,250 | 6,250 | - | - | Restricted Stock Units | |
David Szekeres | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.31 per share. | 13 Jul 2023 | 2,012 | 33,754 (0%) | 0% | 1.3 | 2,636 | Common Stock |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2023 | 1,250 | 31,202 (0%) | 0% | - | Common Stock | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2023 | 1,933 | 26,170 (0%) | 0% | - | Common Stock | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2023 | 1,933 | 9,896 | - | - | Restricted Stock Units | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2023 | 552 | 2,760 | - | - | Restricted Stock Units | |
Lisa Peraza | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.31 per share. | 13 Jul 2023 | 860 | 25,310 (0%) | 0% | 1.3 | 1,127 | Common Stock |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2023 | 552 | 24,237 (0%) | 0% | - | Common Stock | |
Craig A. Collard | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.45 per share. | 22 May 2023 | 691 | 37,188 (0%) | 0% | 1.5 | 1,002 | Common Stock |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2023 | 4,564 | 48,660 (0%) | 0% | - | Common Stock | |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2023 | 4,564 | 27,936 | - | - | Restricted Stock Units | |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2023 | 1,250 | 7,500 | - | - | Restricted Stock Units | |
John W. Poyhonen | President & CCO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.88 per share. | 13 Apr 2023 | 2,012 | 46,648 (0%) | 0% | 2.9 | 5,795 | Common Stock |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2023 | 1,250 | 44,096 (0%) | 0% | - | Common Stock | |
Kimberly J. Manhard | EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2023 | 4,564 | 29,747 (0%) | 0% | - | Common Stock | |
Kimberly J. Manhard | EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2023 | 4,564 | 27,936 | - | - | Restricted Stock Units | |
Kimberly J. Manhard | EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2023 | 1,250 | 7,500 | - | - | Restricted Stock Units | |
Kimberly J. Manhard | EVP, Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.88 per share. | 13 Apr 2023 | 1,417 | 28,330 (0%) | 0% | 2.9 | 4,081 | Common Stock |
Kimberly J. Manhard | EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2023 | 1,250 | 25,183 (0%) | 0% | - | Common Stock | |
David Szekeres | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.88 per share. | 13 Apr 2023 | 2,012 | 29,952 (0%) | 0% | 2.9 | 5,795 | Common Stock |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2023 | 1,250 | 27,400 (0%) | 0% | - | Common Stock | |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2023 | 4,564 | 31,964 (0%) | 0% | - | Common Stock | |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2023 | 1,250 | 7,500 | - | - | Restricted Stock Units | |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2023 | 4,564 | 27,936 | - | - | Restricted Stock Units | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2023 | 552 | 22,613 (0%) | 0% | - | Common Stock | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2023 | 1,932 | 11,829 | - | - | Restricted Stock Units | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2023 | 552 | 3,312 | - | - | Restricted Stock Units | |
Lisa Peraza | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.88 per share. | 13 Apr 2023 | 860 | 23,685 (0%) | 0% | 2.9 | 2,477 | Common Stock |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2023 | 1,932 | 24,545 (0%) | 0% | - | Common Stock | |
Craig A. Collard | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 3,000,000 | 3,000,000 | - | - | Employee Stock Option (Right to Buy) | |
Craig A. Collard | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 4,250,000 | 4,250,000 | - | - | Employee Performance Stock Option (Right to Buy) | |
Craig A. Collard | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 250,000 | 250,000 | - | - | Restricted Stock Units | |
Adam Morgan | Director, See Notes 2 & 3 | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2023 | 227,272 | 227,272 | - | - | Stock Option (Right to Buy) | |
Adam Morgan | Director, See Notes 2 & 3 | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2023 | 37,879 | 37,879 (0%) | 0% | 0 | Common Stock | |
Barry D. Quart | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2023 | 850,000 | 850,000 | - | - | Employee Stock Option (Right to Buy) | |
John W. Poyhonen | President & CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2023 | 66,385 | 66,385 | - | - | Performance Stock Units | |
Kimberly J. Manhard | Director, EVP, Drug Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2023 | 149,365 | 149,365 | - | - | Performance Stock Units | |
David Szekeres | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2023 | 49,788 | 49,788 | - | - | Performance Stock Units | |
Lisa Peraza | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2023 | 42,631 | 42,631 | - | - | Performance Stock Units | |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 3,645 | 167,086 (0%) | 0% | - | Common Stock | |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 16,122 | 114,807 | - | - | Restricted Stock Units | |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 3,645 | 25,521 | - | - | Restricted Stock Units | |
Barry D. Quart | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.17 per share. | 13 Jan 2023 | 5,219 | 177,989 (0%) | 0% | 3.2 | 16,544 | Common Stock |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 16,122 | 183,208 (0%) | 0% | - | Common Stock | |
Barry D. Quart | Director, Chief Executive Officer | Other type of transaction at price $ 3.27 per share. | 13 Jan 2023 | 1,655 | 163,441 (0%) | 0% | 3.3 | 5,416 | Common Stock |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 4,564 | 32,500 | - | - | Restricted Stock Units | |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 1,250 | 40,294 (0%) | 0% | - | Common Stock | |
John W. Poyhonen | President & CCO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.17 per share. | 13 Jan 2023 | 2,012 | 42,846 (0%) | 0% | 3.2 | 6,378 | Common Stock |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 1,250 | 8,750 | - | - | Restricted Stock Units | |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 4,564 | 44,858 (0%) | 0% | - | Common Stock | |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 1,250 | 8,750 | - | - | Restricted Stock Units | |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 1,250 | 21,381 (0%) | 0% | - | Common Stock | |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 4,564 | 32,500 | - | - | Restricted Stock Units | |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 4,564 | 25,945 (0%) | 0% | - | Common Stock | |
Kimberly J. Manhard | Director, EVP, Drug Development | Other type of transaction at price $ 3.27 per share. | 13 Jan 2023 | 1,655 | 20,131 (0%) | 0% | 3.3 | 5,416 | Common Stock |
Kimberly J. Manhard | Director, EVP, Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.17 per share. | 13 Jan 2023 | 2,012 | 23,933 (0%) | 0% | 3.2 | 6,378 | Common Stock |
David Szekeres | EVP, Chief Operating Officer | Other type of transaction at price $ 3.27 per share. | 13 Jan 2023 | 1,654 | 22,348 (0%) | 0% | 3.3 | 5,413 | Common Stock |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 4,564 | 32,500 | - | - | Restricted Stock Units | |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 1,250 | 8,750 | - | - | Restricted Stock Units | |
David Szekeres | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.17 per share. | 13 Jan 2023 | 2,012 | 26,150 (0%) | 0% | 3.2 | 6,378 | Common Stock |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 4,564 | 28,162 (0%) | 0% | - | Common Stock | |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 1,250 | 23,598 (0%) | 0% | - | Common Stock | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 1,933 | 13,761 | - | - | Restricted Stock Units | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 552 | 3,864 | - | - | Restricted Stock Units | |
Lisa Peraza | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.17 per share. | 13 Jan 2023 | 1,013 | 22,061 (0%) | 0% | 3.2 | 3,211 | Common Stock |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 1,933 | 23,074 (0%) | 0% | - | Common Stock | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 552 | 21,141 (0%) | 0% | - | Common Stock | |
Stephen R. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 38,580 | 52,032 (0%) | 0% | 0 | Common Stock | |
Stephen R. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 77,160 | 77,160 | - | - | Stock Option (Right to Buy) | |
Craig A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 77,160 | 77,160 | - | - | Stock Option (Right to Buy) | |
Craig A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 38,580 | 51,872 (0%) | 0% | 0 | Common Stock | |
Christian Waage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 38,580 | 52,232 (0%) | 0% | 0 | Common Stock | |
Christian Waage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 77,160 | 77,160 | - | - | Stock Option (Right to Buy) | |
Susan Rodriguez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 77,160 | 77,160 | - | - | Stock Option (Right to Buy) | |
Susan Rodriguez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 38,580 | 55,282 (0%) | 0% | 0 | Common Stock | |
Sharmila Dissanaike | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 77,160 | 77,160 | - | - | Stock Option (Right to Buy) | |
Sharmila Dissanaike | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 38,580 | 55,282 (0%) | 0% | 0 | Common Stock | |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 16,122 | 167,005 (0%) | 0% | - | Common Stock | |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 16,122 | 130,929 | - | - | Restricted Stock Units | |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 3,646 | 29,166 | - | - | Restricted Stock Units | |
Barry D. Quart | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.76 per share. | 13 Oct 2022 | 5,219 | 161,786 (0%) | 0% | 3.8 | 19,623 | Common Stock |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 3,646 | 150,883 (0%) | 0% | - | Common Stock | |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 1,250 | 10,000 | - | - | Restricted Stock Units | |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 1,250 | 36,492 (0%) | 0% | - | Common Stock | |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 4,564 | 41,056 (0%) | 0% | - | Common Stock | |
John W. Poyhonen | President & CCO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.76 per share. | 13 Oct 2022 | 2,012 | 39,044 (0%) | 0% | 3.8 | 7,565 | Common Stock |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 4,564 | 37,064 | - | - | Restricted Stock Units | |
Kimberly J. Manhard | Director, EVP, Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.76 per share. | 13 Oct 2022 | 2,012 | 18,476 (0%) | 0% | 3.8 | 7,565 | Common Stock |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 4,564 | 37,064 | - | - | Restricted Stock Units | |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 1,250 | 10,000 | - | - | Restricted Stock Units | |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 4,564 | 20,488 (0%) | 0% | - | Common Stock | |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 1,250 | 15,924 (0%) | 0% | - | Common Stock | |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 4,564 | 37,064 | - | - | Restricted Stock Units | |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 1,250 | 18,142 (0%) | 0% | - | Common Stock | |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 4,564 | 22,706 (0%) | 0% | - | Common Stock | |
David Szekeres | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.76 per share. | 13 Oct 2022 | 2,012 | 20,694 (0%) | 0% | 3.8 | 7,565 | Common Stock |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 1,250 | 10,000 | - | - | Restricted Stock Units | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 553 | 19,518 (0%) | 0% | - | Common Stock | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 1,932 | 15,694 | - | - | Restricted Stock Units | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 553 | 4,416 | - | - | Restricted Stock Units | |
Lisa Peraza | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.76 per share. | 13 Oct 2022 | 861 | 20,589 (0%) | 0% | 3.8 | 3,237 | Common Stock |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 1,932 | 21,450 (0%) | 0% | - | Common Stock | |
John W. Poyhonen | President & CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2022 | 165,961 | 165,961 | - | - | Employee Stock Option (Right to Buy) | |
Kimberly J. Manhard | Director, EVP, Drug Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2022 | 165,961 | 165,961 | - | - | Employee Stock Option (Right to Buy) | |
David Szekeres | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2022 | 165,961 | 165,961 | - | - | Employee Stock Option (Right to Buy) | |
Lisa Peraza | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2022 | 60,902 | 60,902 | - | - | Employee Stock Option (Right to Buy) | |
Barry D. Quart | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.01 per share. | 13 Jul 2022 | 5,219 | 147,237 (0%) | 0% | 3.0 | 15,709 | Common Stock |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 16,122 | 147,051 | - | - | Restricted Stock Units | |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 3,646 | 32,812 | - | - | Restricted Stock Units | |
Barry D. Quart | Director, Chief Executive Officer | Other type of transaction at price $ 3.84 per share. | 13 Jul 2022 | 1,504 | 132,688 (0%) | 0% | 3.8 | 5,778 | Common Stock |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 3,646 | 136,334 (0%) | 0% | - | Common Stock | |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 16,122 | 152,456 (0%) | 0% | - | Common Stock | |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 4,564 | 37,254 (0%) | 0% | - | Common Stock | |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 4,564 | 41,628 | - | - | Restricted Stock Units | |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 1,250 | 32,690 (0%) | 0% | - | Common Stock | |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 1,250 | 11,250 | - | - | Restricted Stock Units | |
John W. Poyhonen | President & CCO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.01 per share. | 13 Jul 2022 | 2,012 | 35,242 (0%) | 0% | 3.0 | 6,056 | Common Stock |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 4,564 | 41,628 | - | - | Restricted Stock Units | |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 1,250 | 12,122 (0%) | 0% | - | Common Stock | |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 4,564 | 16,686 (0%) | 0% | - | Common Stock | |
Kimberly J. Manhard | Director, EVP, Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.01 per share. | 13 Jul 2022 | 2,012 | 14,674 (0%) | 0% | 3.0 | 6,056 | Common Stock |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 1,250 | 11,250 | - | - | Restricted Stock Units | |
David Szekeres | EVP, Chief Operating Officer | Other type of transaction at price $ 3.84 per share. | 13 Jul 2022 | 1,505 | 13,090 (0%) | 0% | 3.8 | 5,782 | Common Stock |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 1,250 | 14,340 (0%) | 0% | - | Common Stock | |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 4,564 | 18,904 (0%) | 0% | - | Common Stock | |
David Szekeres | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.01 per share. | 13 Jul 2022 | 2,012 | 16,892 (0%) | 0% | 3.0 | 6,056 | Common Stock |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 1,250 | 11,250 | - | - | Restricted Stock Units | |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 4,564 | 41,628 | - | - | Restricted Stock Units | |
Lisa Peraza | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.01 per share. | 13 Jul 2022 | 860 | 18,965 (0%) | 0% | 3.0 | 2,589 | Common Stock |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 552 | 4,969 | - | - | Restricted Stock Units | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 1,933 | 17,626 | - | - | Restricted Stock Units | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 552 | 17,892 (0%) | 0% | - | Common Stock | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 1,933 | 19,825 (0%) | 0% | - | Common Stock | |
Kimberly J. Manhard | Director, EVP, Drug Development | Sale of securities on an exchange or to another person at price $ 4.76 per share. | 03 May 2022 | 1,504 | 10,872 (0%) | 0% | 4.8 | 7,154 | Common Stock |
Kimberly J. Manhard | Director, EVP, Drug Development | Other type of transaction at price $ 3.84 per share. | 03 May 2022 | 1,504 | 12,376 (0%) | 0% | 3.8 | 5,778 | Common Stock |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 3,646 | 120,281 (0%) | 0% | - | Common Stock | |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 16,122 | 163,173 | - | - | Restricted Stock Units | |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 3,646 | 36,458 | - | - | Restricted Stock Units | |
Barry D. Quart | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.07 per share. | 13 Apr 2022 | 5,219 | 131,184 (0%) | 0% | 6.1 | 31,679 | Common Stock |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 16,122 | 136,403 (0%) | 0% | - | Common Stock | |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 4,564 | 33,452 (0%) | 0% | - | Common Stock | |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 4,564 | 46,192 | - | - | Restricted Stock Units | |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 1,250 | 12,500 | - | - | Restricted Stock Units | |
John W. Poyhonen | President & CCO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.07 per share. | 13 Apr 2022 | 2,012 | 31,440 (0%) | 0% | 6.1 | 12,213 | Common Stock |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 1,250 | 28,888 (0%) | 0% | - | Common Stock | |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 4,564 | 12,884 (0%) | 0% | - | Common Stock | |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 1,250 | 12,500 | - | - | Restricted Stock Units | |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 4,564 | 46,192 | - | - | Restricted Stock Units | |
Kimberly J. Manhard | Director, EVP, Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.07 per share. | 13 Apr 2022 | 2,012 | 10,872 (0%) | 0% | 6.1 | 12,213 | Common Stock |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 1,250 | 8,320 (0%) | 0% | - | Common Stock | |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 4,564 | 13,597 (0%) | 0% | - | Common Stock | |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 4,564 | 46,192 | - | - | Restricted Stock Units | |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 1,250 | 12,500 | - | - | Restricted Stock Units | |
David Szekeres | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.07 per share. | 13 Apr 2022 | 2,012 | 11,585 (0%) | 0% | 6.1 | 12,213 | Common Stock |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 1,250 | 9,033 (0%) | 0% | - | Common Stock | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 1,932 | 19,559 | - | - | Restricted Stock Units | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 552 | 5,521 | - | - | Restricted Stock Units | |
Lisa Peraza | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.07 per share. | 13 Apr 2022 | 860 | 17,340 (0%) | 0% | 6.1 | 5,220 | Common Stock |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 1,932 | 18,200 (0%) | 0% | - | Common Stock | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 552 | 16,268 (0%) | 0% | - | Common Stock | |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 3,646 | 105,732 (0%) | 0% | - | Common Stock | |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 16,122 | 179,295 | - | - | Restricted Stock Units | |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 3,646 | 40,104 | - | - | Restricted Stock Units | |
Barry D. Quart | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.30 per share. | 13 Jan 2022 | 5,219 | 116,635 (0%) | 0% | 8.3 | 43,318 | Common Stock |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 16,122 | 121,854 (0%) | 0% | - | Common Stock | |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 4,564 | 50,756 | - | - | Restricted Stock Units | |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 1,250 | 25,086 (0%) | 0% | - | Common Stock | |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 4,564 | 29,650 (0%) | 0% | - | Common Stock | |
John W. Poyhonen | President & CCO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.30 per share. | 13 Jan 2022 | 2,012 | 27,638 (0%) | 0% | 8.3 | 16,700 | Common Stock |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 1,250 | 13,750 | - | - | Restricted Stock Units | |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 4,564 | 9,082 (0%) | 0% | - | Common Stock | |
Kimberly J. Manhard | Director, EVP, Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.30 per share. | 13 Jan 2022 | 2,012 | 7,070 (0%) | 0% | 8.3 | 16,700 | Common Stock |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 1,250 | 13,750 | - | - | Restricted Stock Units | |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 4,564 | 50,756 | - | - | Restricted Stock Units | |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 1,250 | 4,518 (0%) | 0% | - | Common Stock | |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 4,564 | 50,756 | - | - | Restricted Stock Units | |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 1,250 | 5,231 (0%) | 0% | - | Common Stock | |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 4,564 | 9,795 (0%) | 0% | - | Common Stock | |
David Szekeres | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.30 per share. | 13 Jan 2022 | 2,012 | 7,783 (0%) | 0% | 8.3 | 16,700 | Common Stock |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 1,250 | 13,750 | - | - | Restricted Stock Units | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 1,933 | 16,682 (0%) | 0% | - | Common Stock | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 1,933 | 21,491 | - | - | Restricted Stock Units | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 552 | 6,073 | - | - | Restricted Stock Units | |
Lisa Peraza | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.30 per share. | 13 Jan 2022 | 966 | 15,716 (0%) | 0% | 8.3 | 8,018 | Common Stock |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2022 | 552 | 14,749 (0%) | 0% | - | Common Stock | |
Stephen R. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2021 | 10,452 | 13,452 (0%) | 0% | 0 | Common Stock | |
Stephen R. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2021 | 20,903 | 20,903 | - | - | Stock Option (Right to Buy) | |
Susan Rodriguez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2021 | 10,452 | 16,702 (0%) | 0% | 0 | Common Stock | |
Susan Rodriguez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2021 | 20,903 | 20,903 | - | - | Stock Option (Right to Buy) | |
Sharmila Dissanaike | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2021 | 20,903 | 20,903 | - | - | Stock Option (Right to Buy) | |
Sharmila Dissanaike | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2021 | 10,452 | 16,702 (0%) | 0% | 0 | Common Stock | |
Craig A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2021 | 20,903 | 20,903 | - | - | Stock Option (Right to Buy) | |
Craig A. Johnson | Director | Sale of securities on an exchange or to another person at price $ 9.73 per share. | 21 Dec 2021 | 250 | 2,840 (0%) | 0% | 9.7 | 2,432 | Common Stock |
Craig A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2021 | 10,452 | 13,292 (0%) | 0% | 0 | Common Stock | |
Christian Waage | Director | Sale of securities on an exchange or to another person at price $ 9.73 per share. | 21 Dec 2021 | 300 | 3,200 (0%) | 0% | 9.7 | 2,920 | Common Stock |
Christian Waage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2021 | 20,903 | 20,903 | - | - | Stock Option (Right to Buy) | |
Christian Waage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2021 | 10,452 | 13,652 (0%) | 0% | 0 | Common Stock | |
John W. Poyhonen | President & CCO | Other type of transaction at price $ 9.36 per share. | 29 Oct 2021 | 817 | 23,836 (0%) | 0% | 9.4 | 7,646 | Common Stock |
Barry D. Quart | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2021 | 390,834 | 390,834 | - | - | Employee Stock Option (Right to Buy) | |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2021 | 3,646 | 103,049 (0%) | 0% | - | Common Stock | |
Barry D. Quart | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.55 per share. | 13 Oct 2021 | 963 | 102,086 (0%) | 0% | 10.6 | 10,160 | Common Stock |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2021 | 3,646 | 43,750 | - | - | Restricted Stock Units | |
Barry D. Quart | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2021 | 195,417 | 195,417 | - | - | Restricted Stock Units | |
John W. Poyhonen | President & CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2021 | 92,200 | 92,200 | - | - | Employee Stock Option (Right to Buy) | |
John W. Poyhonen | President & CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2021 | 55,320 | 55,320 | - | - | Restricted Stock Units | |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2021 | 1,250 | 15,000 | - | - | Restricted Stock Units | |
John W. Poyhonen | President & CCO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.55 per share. | 13 Oct 2021 | 433 | 23,019 (0%) | 0% | 10.5 | 4,568 | Common Stock |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2021 | 1,250 | 23,452 (0%) | 0% | - | Common Stock | |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2021 | 1,250 | 3,701 (0%) | 0% | - | Common Stock | |
Kimberly J. Manhard | Director, EVP, Drug Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2021 | 55,320 | 55,320 | - | - | Restricted Stock Units | |
Kimberly J. Manhard | Director, EVP, Drug Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2021 | 92,200 | 92,200 | - | - | Employee Stock Option (Right to Buy) | |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2021 | 1,250 | 15,000 | - | - | Restricted Stock Units | |
Kimberly J. Manhard | Director, EVP, Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.55 per share. | 13 Oct 2021 | 433 | 3,268 (0%) | 0% | 10.5 | 4,568 | Common Stock |
David Szekeres | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2021 | 55,320 | 55,320 | - | - | Restricted Stock Units | |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2021 | 1,250 | 4,414 (0%) | 0% | - | Common Stock | |
David Szekeres | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.55 per share. | 13 Oct 2021 | 433 | 3,981 (0%) | 0% | 10.5 | 4,568 | Common Stock |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2021 | 1,250 | 15,000 | - | - | Restricted Stock Units | |
David Szekeres | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2021 | 92,200 | 92,200 | - | - | Employee Stock Option (Right to Buy) | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2021 | 552 | 14,388 (0%) | 0% | - | Common Stock | |
Lisa Peraza | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2021 | 23,424 | 23,424 | - | - | Restricted Stock Units | |
Lisa Peraza | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2021 | 13,013 | 13,013 | - | - | Employee Stock Option (Right to Buy) | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2021 | 552 | 6,625 | - | - | Restricted Stock Units | |
Lisa Peraza | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.55 per share. | 13 Oct 2021 | 191 | 14,197 (0%) | 0% | 10.5 | 2,015 | Common Stock |
Craig A. Johnson | Director | Sale of securities on an exchange or to another person at price $ 12.30 per share. | 21 Sep 2021 | 250 | 3,090 (0%) | 0% | 12.3 | 3,074 | Common Stock |
Christian Waage | Director | Sale of securities on an exchange or to another person at price $ 12.31 per share. | 21 Sep 2021 | 300 | 3,500 (0%) | 0% | 12.3 | 3,692 | Common Stock |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2021 | 3,645 | 100,366 (0%) | 0% | - | Common Stock | |
Barry D. Quart | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.48 per share. | 13 Jul 2021 | 963 | 99,403 (0%) | 0% | 13.5 | 12,981 | Common Stock |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2021 | 3,645 | 47,396 | - | - | Restricted Stock Units | |
Barry D. Quart | Director, Chief Executive Officer | Other type of transaction at price $ 13.90 per share. | 13 Jul 2021 | 1,529 | 96,721 (0%) | 0% | 13.9 | 21,249 | Common Stock |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2021 | 1,250 | 16,250 | - | - | Restricted Stock Units | |
John W. Poyhonen | President & CCO | Other type of transaction at price $ 13.90 per share. | 13 Jul 2021 | 971 | 21,385 (0%) | 0% | 13.9 | 13,494 | Common Stock |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2021 | 1,250 | 22,635 (0%) | 0% | - | Common Stock | |
John W. Poyhonen | President & CCO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.48 per share. | 13 Jul 2021 | 433 | 22,202 (0%) | 0% | 13.5 | 5,837 | Common Stock |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2021 | 1,250 | 2,884 (0%) | 0% | - | Common Stock | |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2021 | 1,250 | 16,250 | - | - | Restricted Stock Units | |
Kimberly J. Manhard | Director, EVP, Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.48 per share. | 13 Jul 2021 | 433 | 2,451 (0%) | 0% | 13.5 | 5,837 | Common Stock |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2021 | 1,250 | 16,250 | - | - | Restricted Stock Units | |
David Szekeres | EVP, Chief Operating Officer | Other type of transaction at price $ 13.90 per share. | 13 Jul 2021 | 1,530 | 2,347 (0%) | 0% | 13.9 | 21,263 | Common Stock |
David Szekeres | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.48 per share. | 13 Jul 2021 | 433 | 3,164 (0%) | 0% | 13.5 | 5,837 | Common Stock |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2021 | 1,250 | 3,597 (0%) | 0% | - | Common Stock | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2021 | 552 | 14,027 (0%) | 0% | - | Common Stock | |
Lisa Peraza | VP, Chief Accounting Officer | Other type of transaction at price $ 13.90 per share. | 13 Jul 2021 | 1,530 | 13,475 (0%) | 0% | 13.9 | 21,263 | Common Stock |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2021 | 552 | 7,177 | - | - | Restricted Stock Units | |
Lisa Peraza | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.48 per share. | 13 Jul 2021 | 191 | 13,836 (0%) | 0% | 13.5 | 2,575 | Common Stock |
Craig A. Johnson | Director | Sale of securities on an exchange or to another person at price $ 15.20 per share. | 21 Jun 2021 | 250 | 3,340 (0%) | 0% | 15.2 | 3,801 | Common Stock |
Christian Waage | Director | Sale of securities on an exchange or to another person at price $ 15.20 per share. | 21 Jun 2021 | 300 | 3,800 (0%) | 0% | 15.2 | 4,559 | Common Stock |
Kimberly J. Manhard | Director, EVP, Drug Development | Sale of securities on an exchange or to another person at price $ 17.66 per share. | 03 May 2021 | 1,529 | 1,634 (0%) | 0% | 17.7 | 27,009 | Common Stock |
Kimberly J. Manhard | Director, EVP, Drug Development | Other type of transaction at price $ 13.90 per share. | 03 May 2021 | 1,529 | 3,163 (0%) | 0% | 13.9 | 21,249 | Common Stock |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 1,250 | 17,500 | - | - | Restricted Stock Units | |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 1,250 | 20,847 (0%) | 0% | - | Common Stock | |
John W. Poyhonen | President & CCO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.66 per share. | 13 Apr 2021 | 433 | 20,414 (0%) | 0% | 16.7 | 7,214 | Common Stock |
Kimberly J. Manhard | Director, EVP, Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.66 per share. | 13 Apr 2021 | 433 | 1,634 (0%) | 0% | 16.7 | 7,214 | Common Stock |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 1,250 | 17,500 | - | - | Restricted Stock Units | |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 1,250 | 2,067 (0%) | 0% | - | Common Stock | |
David Szekeres | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.66 per share. | 13 Apr 2021 | 433 | 817 (0%) | 0% | 16.7 | 7,214 | Common Stock |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 1,250 | 17,500 | - | - | Restricted Stock Units | |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 1,250 | 1,250 (0%) | 0% | - | Common Stock | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 552 | 12,136 (0%) | 0% | - | Common Stock | |
Lisa Peraza | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.66 per share. | 13 Apr 2021 | 191 | 11,945 (0%) | 0% | 16.7 | 3,182 | Common Stock |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 552 | 7,729 | - | - | Restricted Stock Units | |
Craig A. Johnson | Director | Sale of securities on an exchange or to another person at price $ 17.22 per share. | 06 Apr 2021 | 250 | 3,590 (0%) | 0% | 17.2 | 4,305 | Common Stock |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2021 | 3,646 | 92,872 (0%) | 0% | - | Common Stock | |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2021 | 3,646 | 54,687 | - | - | Restricted Stock Units | |
Barry D. Quart | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.16 per share. | 13 Jan 2021 | 963 | 91,909 (0%) | 0% | 18.2 | 17,488 | Common Stock |
John W. Poyhonen | President & CCO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.16 per share. | 13 Jan 2021 | 433 | 19,597 (0%) | 0% | 18.2 | 7,863 | Common Stock |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2021 | 1,250 | 20,030 (0%) | 0% | - | Common Stock | |
John W. Poyhonen | President & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2021 | 1,250 | 18,750 | - | - | Restricted Stock Units | |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2021 | 1,250 | 1,250 (0%) | 0% | - | Common Stock | |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2021 | 1,250 | 18,750 | - | - | Restricted Stock Units | |
Kimberly J. Manhard | Director, EVP, Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.16 per share. | 13 Jan 2021 | 433 | 817 (0%) | 0% | 18.2 | 7,863 | Common Stock |
David Szekeres | EVP, Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 18.09 per share. | 13 Jan 2021 | 827 | 0 (0%) | 0% | 18.1 | 14,960 | Common Stock |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2021 | 1,250 | 18,750 | - | - | Restricted Stock Units | |
David Szekeres | EVP, Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2021 | 1,250 | 1,250 (0%) | 0% | - | Common Stock | |
David Szekeres | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.16 per share. | 13 Jan 2021 | 423 | 827 (0%) | 0% | 18.2 | 7,682 | Common Stock |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2021 | 552 | 11,811 (0%) | 0% | - | Common Stock | |
Lisa Peraza | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2021 | 552 | 8,281 | - | - | Restricted Stock Units | |
Lisa Peraza | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.16 per share. | 13 Jan 2021 | 227 | 11,584 (0%) | 0% | 18.2 | 4,122 | Common Stock |
David Szekeres | EVP, Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 19.66 per share. | 08 Jan 2021 | 3,571 | 0 (0%) | 0% | 19.7 | 70,219 | Common Stock |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.00 per share. | 22 Dec 2020 | 10,000 | 10,000 (0%) | 0% | 13 | 130,000 | Common Stock |
Kimberly J. Manhard | Director, EVP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2020 | 10,000 | 48,416 | - | - | Employee Stock Option (Right to Buy) | |
Kimberly J. Manhard | Director, EVP, Drug Development | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 22 Dec 2020 | 10,000 | 0 (0%) | 0% | 20 | 200,000 | Common Stock |
Stephen R. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2020 | 3,000 | 3,000 (0%) | 0% | 0 | Common Stock | |
Stephen R. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2020 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
Craig A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2020 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
Craig A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2020 | 3,000 | 3,840 (0%) | 0% | 0 | Common Stock | |
Christian Waage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2020 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
Christian Waage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2020 | 3,000 | 4,400 (0%) | 0% | 0 | Common Stock | |
John W. Poyhonen | President & CCO | Other type of transaction at price $ 11.65 per share. | 30 Oct 2020 | 637 | 18,780 (0%) | 0% | 11.7 | 7,423 | Common Stock |
Barry D. Quart | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2020 | 350,000 | 350,000 | - | - | Employee Stock Option (Right to Buy) | |
Barry D. Quart | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2020 | 58,333 | 58,333 | - | - | Restricted Stock Units | |
Barry D. Quart | Director, Chief Executive Officer | Other type of transaction at price $ 12.12 per share. | 13 Oct 2020 | 1,158 | 89,226 (0%) | 0% | 12.1 | 14,036 | Common Stock |
John W. Poyhonen | President & CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2020 | 170,000 | 170,000 | - | - | Employee Stock Option (Right to Buy) | |
John W. Poyhonen | President & CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2020 | 20,000 | 20,000 | - | - | Restricted Stock Units | |
Kimberly J. Manhard | Director, EVP, Drug Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2020 | 20,000 | 20,000 | - | - | Restricted Stock Units | |
Kimberly J. Manhard | Director, EVP, Drug Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2020 | 120,000 | 120,000 | - | - | Employee Stock Option (Right to Buy) | |
Stephen R. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2020 | 765 | 765 | - | - | Stock Option (Right to Buy) | |
Christian Waage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2020 | 437 | 437 | - | - | Stock Option (Right to Buy) | |
Lisa Peraza | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2020 | 103,000 | 103,000 | - | - | Employee Stock Option (Right to Buy) | |
Lisa Peraza | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2020 | 8,833 | 8,833 | - | - | Restricted Stock Units | |
Kimberly J. Manhard | Director, Executive VP, Drug Development | Sale of securities on an exchange or to another person at price $ 13.97 per share. | 01 May 2020 | 1,158 | 0 (0%) | 0% | 14.0 | 16,176 | Common Stock |
Kimberly J. Manhard | Director, Executive VP, Drug Development | Other type of transaction at price $ 12.12 per share. | 01 May 2020 | 1,158 | 1,158 (0%) | 0% | 12.1 | 14,036 | Common Stock |
Stephen R. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2020 | 1,426 | 1,426 | - | - | Stock Option (Right to Buy) | |
Christian Waage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2020 | 713 | 713 | - | - | Stock Option (Right to Buy) | |
Barry D. Quart | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2019 | 6,584 | 88,068 (0%) | 0% | 0 | Common Stock | |
Kevin C. Tang | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2019 | 297,714 | 5,017,203 (5%) | 0% | 0 | Common Stock | |
Kevin C. Tang | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2019 | 121,500 | 5,017,203 (5%) | 0% | 0 | Common Stock | |
Kevin C. Tang | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2019 | 41,189 | 5,017,203 (5%) | 0% | 0 | Common Stock | |
Kevin C. Tang | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2019 | 201,000 | 5,017,203 (5%) | 0% | 0 | Common Stock | |
Kevin C. Tang | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2019 | 80,400 | 5,017,203 (5%) | 0% | 0 | Common Stock | |
Kevin C. Tang | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2019 | 20,402 | 5,017,203 (5%) | 0% | 0 | Common Stock | |
Kevin C. Tang | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2019 | 20,402 | 5,017,203 (5%) | 0% | 0 | Common Stock | |
Kevin C. Tang | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2019 | 230,000 | 5,017,203 (5%) | 0% | 0 | Common Stock | |
Kevin C. Tang | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2019 | 9,000 | 5,017,203 (5%) | 0% | 0 | Common Stock | |
Barry D. Quart | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2019 | 325,000 | 325,000 | - | - | Employee Stock Option (Right to Buy) | |
John W. Poyhonen | Director, EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2019 | 55,562 | 55,562 | - | - | Employee Stock Option (Right to Buy) | |
Kevin C. Tang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2019 | 17,000 | 17,000 | - | - | Stock Option (right to buy) | |
Kimberly J. Manhard | Director, Executive VP, Drug Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2019 | 120,000 | 120,000 | - | - | Employee Stock Option (Right to Buy) | |
Stephen R. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2019 | 15,500 | 15,500 | - | - | Stock Option (Right to Buy) | |
Robert E. Hoffman | CFO & SVP, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2019 | 100,000 | 100,000 | - | - | Employee Stock Option (Right to Buy) | |
Craig A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2019 | 23,000 | 23,000 | - | - | Stock Option (Right to Buy) | |
Christian Waage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2019 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) | |
Kimberly J. Manhard | Director, Executive VP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2019 | 24,000 | 58,416 | - | - | Employee Stock Option (Right to Buy) | |
Kimberly J. Manhard | Director, Executive VP, Drug Development | Sale of securities on an exchange or to another person at price $ 26.00 per share. | 29 Nov 2019 | 24,000 | 0 (0%) | 0% | 26 | 624,000 | Common Stock |
Kimberly J. Manhard | Director, Executive VP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.00 per share. | 29 Nov 2019 | 24,000 | 24,000 (0%) | 0% | 13 | 312,000 | Common Stock |
Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 17.50 per share. | 04 Oct 2019 | 285,714 | 5,799,810 (6%) | 0% | 17.5 | 4,999,995 | Common Stock |
Barry D. Quart | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 17.50 per share. | 03 Oct 2019 | 4,571 | 94,652 (0%) | 0% | 17.5 | 79,993 | Common Stock |
Barry D. Quart | Director, Chief Executive Officer | Other type of transaction at price $ 18.43 per share. | 03 Oct 2019 | 806 | 90,081 (0%) | 0% | 18.4 | 14,853 | Common Stock |
John W. Poyhonen | Director, EVP, Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 17.50 per share. | 03 Oct 2019 | 5,143 | 18,143 (0%) | 0% | 17.5 | 90,003 | Common Stock |
Stephen R. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2019 | 750 | 750 | - | - | Stock Option (Right to Buy) | |
Stephen R. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2019 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
John W. Poyhonen | Director, EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2019 | 300,000 | 300,000 | - | - | Employee Stock Option (Right to Buy) | |
John W. Poyhonen | Director | Purchase of securities on an exchange or from another person at price $ 17.55 per share. | 22 May 2019 | 3,000 | 13,000 (0%) | 0% | 17.6 | 52,650 | Common Stock |
Christian Waage | Director | Purchase of securities on an exchange or from another person at price $ 18.04 per share. | 15 May 2019 | 1,400 | 1,400 (0%) | 0% | 18.0 | 25,262 | Common Stock |
Kimberly J. Manhard | Executive VP, Drug Development | Other type of transaction at price $ 18.43 per share. | 01 May 2019 | 1,109 | 1,109 (0%) | 0% | 18.4 | 20,437 | Common Stock |
Kimberly J. Manhard | Executive VP, Drug Development | Sale of securities on an exchange or to another person at price $ 18.86 per share. | 01 May 2019 | 1,109 | 0 (0%) | 0% | 18.9 | 20,918 | Common Stock |
Kevin C. Tang | None | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2018 | 1,992 | 5,790,245 (7%) | 0% | 0 | Common Stock | |
Kevin C. Tang | None | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2018 | 19,304 | 5,770,941 (7%) | 0% | 0 | Common Stock | |
Kevin C. Tang | None | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2018 | 3,955 | 5,766,986 (7%) | 0% | 0 | Common Stock | |
Kevin C. Tang | None | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2018 | 3,955 | 5,763,031 (7%) | 0% | 0 | Common Stock | |
Kevin C. Tang | None | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2018 | 3,955 | 5,759,076 (7%) | 0% | 0 | Common Stock | |
Kevin C. Tang | None | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2018 | 2,025 | 5,757,051 (7%) | 0% | 0 | Common Stock | |
Kevin C. Tang | None | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2018 | 3,955 | 5,753,096 (7%) | 0% | 0 | Common Stock | |
Kevin C. Tang | None | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2018 | 18,989 | 5,811,226 (7%) | 0% | 0 | Common Stock | |
Kevin C. Tang | None | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2018 | 18,989 | 5,792,237 (7%) | 0% | 0 | Common Stock | |
Barry D. Quart | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2018 | 300,000 | 300,000 | - | - | Employee Stock Option (Right to Buy) | |
John W. Poyhonen | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2018 | 19,500 | 19,500 | - | - | Stock Option (Right to Buy) | |
John W. Poyhonen | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2018 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
Kevin C. Tang | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2018 | 17,000 | 17,000 | - | - | Stock Option (right to buy) | |
Kimberly J. Manhard | Executive VP, Drug Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2018 | 100,000 | 100,000 | - | - | Employee Stock Option (Right to Buy) | |
Robert E. Hoffman | CFO & SVP, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2018 | 71,000 | 71,000 | - | - | Employee Stock Option (Right to Buy) | |
Craig A. Johnson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2018 | 21,000 | 21,000 | - | - | Stock Option (Right to Buy) | |
Christian Waage | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2018 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) | |
Robert H. Rosen | Director, President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2018 | 300,000 | 300,000 | - | - | Employee Stock Option (Right to Buy) | |
Kimberly J. Manhard | Executive VP, Drug Development | Sale of securities on an exchange or to another person at price $ 30.62 per share. | 02 Nov 2018 | 494 | 0 (0%) | 0% | 30.6 | 15,125 | Common Stock |
Kimberly J. Manhard | Executive VP, Drug Development | Other type of transaction at price $ 23.60 per share. | 02 Nov 2018 | 494 | 494 (0%) | 0% | 23.6 | 11,656 | Common Stock |
Kimberly J. Manhard | Executive VP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2018 | 6,000 | 82,416 | - | - | Employee Stock Option (Right to Buy) | |
Kimberly J. Manhard | Executive VP, Drug Development | Sale of securities on an exchange or to another person at price $ 32.07 per share. | 01 Oct 2018 | 6,000 | 0 (0%) | 0% | 32.1 | 192,433 | Common Stock |
Kimberly J. Manhard | Executive VP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.00 per share. | 01 Oct 2018 | 6,000 | 6,000 (0%) | 0% | 13 | 78,000 | Common Stock |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 14 Sep 2018 | 19,675 | 89,275 (0%) | 0% | 7.2 | 141,660 | Common Stock |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2018 | 19,675 | 710,601 | - | - | Employee Stock Option (Right to Buy) | |
Kevin C. Tang | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 35.75 per share. | 12 Sep 2018 | 2,695,000 | 5,830,215 (7%) | 3% | 35.8 | 96,346,250 | Common Stock |
Kimberly J. Manhard | Executive VP, Drug Development | Sale of securities on an exchange or to another person at price $ 38.85 per share. | 02 Jul 2018 | 100 | 0 (0%) | 0% | 38.9 | 3,885 | Common Stock |
Kimberly J. Manhard | Executive VP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.00 per share. | 02 Jul 2018 | 6,000 | 6,000 (0%) | 0% | 13 | 78,000 | Common Stock |
Kimberly J. Manhard | Executive VP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2018 | 6,000 | 88,416 | - | - | Employee Stock Option (Right to Buy) | |
Kimberly J. Manhard | Executive VP, Drug Development | Sale of securities on an exchange or to another person at price $ 37.51 per share. | 02 Jul 2018 | 5,900 | 100 (0%) | 0% | 37.5 | 221,294 | Common Stock |
Robert E. Hoffman | CFO & SVP, Finance | Sale of securities on an exchange or to another person at price $ 38.80 per share. | 02 Jul 2018 | 1,060 | 1,280 (0%) | 0% | 38.8 | 41,123 | Common Stock |
Robert E. Hoffman | CFO & SVP, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2018 | 30,000 | 100,000 | - | - | Employee Stock Option (Right to Buy) | |
Robert E. Hoffman | CFO & SVP, Finance | Other type of transaction at price $ 13.22 per share. | 02 Jul 2018 | 744 | 1,280 (0%) | 0% | 13.2 | 9,834 | Common Stock |
Robert E. Hoffman | CFO & SVP, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.30 per share. | 02 Jul 2018 | 30,000 | 31,280 (0%) | 0% | 15.3 | 459,000 | Common Stock |
Robert E. Hoffman | CFO & SVP, Finance | Sale of securities on an exchange or to another person at price $ 38.15 per share. | 02 Jul 2018 | 28,940 | 2,340 (0%) | 0% | 38.2 | 1,104,107 | Common Stock |
Robert H. Rosen | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 29 Jun 2018 | 95,531 | 98,171 (0%) | 0% | 7.2 | 687,823 | Common Stock |
Robert H. Rosen | Director, President | Sale of securities on an exchange or to another person at price $ 38.13 per share. | 29 Jun 2018 | 92,131 | 6,040 (0%) | 0% | 38.1 | 3,512,918 | Common Stock |
Robert H. Rosen | Director, President | Sale of securities on an exchange or to another person at price $ 38.75 per share. | 29 Jun 2018 | 3,400 | 2,640 (0%) | 0% | 38.8 | 131,765 | Common Stock |
Robert H. Rosen | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 29 Jun 2018 | 129,469 | 132,109 (0%) | 0% | 7.2 | 932,177 | Common Stock |
Robert H. Rosen | Director, President | Sale of securities on an exchange or to another person at price $ 39.14 per share. | 29 Jun 2018 | 75,661 | 56,448 (0%) | 0% | 39.1 | 2,961,122 | Common Stock |
Robert H. Rosen | Director, President | Sale of securities on an exchange or to another person at price $ 40.17 per share. | 29 Jun 2018 | 51,696 | 4,752 (0%) | 0% | 40.2 | 2,076,597 | Common Stock |
Robert H. Rosen | Director, President | Sale of securities on an exchange or to another person at price $ 41.39 per share. | 29 Jun 2018 | 2,112 | 2,640 (0%) | 0% | 41.4 | 87,415 | Common Stock |
Robert H. Rosen | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2018 | 129,469 | 695,531 | - | - | Employee Stock Option (Right to Buy) | |
Robert H. Rosen | Director, President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2018 | 95,531 | 600,000 | - | - | Employee Stock Option (Right to Buy) | |
Barry D. Quart | Director, Chief Executive Officer | Other type of transaction at price $ 13.22 per share. | 21 Jun 2018 | 1,607 | 69,600 (0%) | 0% | 13.2 | 21,241 | Common Stock |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.05 per share. | 21 Jun 2018 | 50,000 | 119,600 (0%) | 0% | 9.1 | 452,500 | Common Stock |
Barry D. Quart | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 39.05 per share. | 21 Jun 2018 | 50,000 | 69,600 (0%) | 0% | 39.1 | 1,952,500 | Common Stock |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2018 | 50,000 | 250,000 | - | - | Employee Stock Option (Right to Buy) | |
Kevin C. Tang | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 26.00 per share. | 29 Mar 2018 | 192,308 | 8,525,215 (13%) | 0% | 26 | 5,000,008 | Common Stock |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Mar 2018 | 100,000 | 730,276 | - | - | Employee Stock Option (Right to Buy) | |
Barry D. Quart | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 29.75 per share. | 19 Mar 2018 | 100,000 | 67,993 (0%) | 0% | 29.8 | 2,975,000 | Common Stock |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 19 Mar 2018 | 100,000 | 167,993 (0%) | 0% | 7.2 | 720,000 | Common Stock |
Kimberly J. Manhard | Executive VP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Mar 2018 | 18,000 | 94,416 | - | - | Employee Stock Option (Right to Buy) | |
Kimberly J. Manhard | Executive VP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.00 per share. | 19 Mar 2018 | 18,000 | 18,000 (0%) | 0% | 13 | 234,000 | Common Stock |
Kimberly J. Manhard | Executive VP, Drug Development | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 19 Mar 2018 | 18,000 | 0 (0%) | 0% | 30 | 540,000 | Common Stock |
Barry D. Quart | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 24.75 per share. | 14 Mar 2018 | 100,000 | 67,993 (0%) | 0% | 24.8 | 2,475,000 | Common Stock |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2018 | 100,000 | 830,276 | - | - | Employee Stock Option(Right to Buy) | |
Barry D. Quart | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. | 14 Mar 2018 | 100,000 | 167,993 (0%) | 0% | 7.2 | 720,000 | Common Stock |
Kimberly J. Manhard | Executive VP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jan 2018 | 7,584 | 112,416 | - | - | Employee Stock Option (Right to Buy) | |
Kimberly J. Manhard | Executive VP, Drug Development | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 10 Jan 2018 | 7,584 | 0 (0%) | 0% | 20 | 151,680 | Common Stock |
Kimberly J. Manhard | Executive VP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.00 per share. | 10 Jan 2018 | 7,584 | 7,584 (0%) | 0% | 13 | 98,592 | Common Stock |
Barry D. Quart | Director, Chief Executive Officer | Other type of transaction at price $ 12.62 per share. | 18 Dec 2017 | 1,684 | 67,993 (0%) | 0% | 12.6 | 21,256 | Common Stock |
Barry D. Quart | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2017 | 310,000 | 310,000 | - | - | Employee Stock Option (Right to Buy) | |
John W. Poyhonen | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2017 | 19,500 | 19,500 | - | - | Stock Option (Right to Buy) | |
Kevin C. Tang | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2017 | 17,000 | 17,000 | - | - | Stock Option (right to buy) | |
Kimberly J. Manhard | Executive VP, Drug Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2017 | 120,000 | 120,000 | - | - | Employee Stock Option (Right to Buy) | |
Robert E. Hoffman | CFO & SVP, Finance | Other type of transaction at price $ 13.05 per share. | 18 Dec 2017 | 536 | 536 (0%) | 0% | 13.0 | 6,993 | Common Stock |
Robert E. Hoffman | CFO & SVP, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2017 | 56,667 | 56,667 | - | - | Employee Stock Option (Right to Buy) | |
Craig A. Johnson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2017 | 21,000 | 21,000 | - | - | Stock Option (Right to Buy) | |
Christian Waage | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2017 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) | |
Robert H. Rosen | Director, President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2017 | 310,000 | 310,000 | - | - | Employee Stock Option (Right to Buy) | |
Kimberly J. Manhard | Executive VP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2017 | 16,292 | 0 | - | - | Stock Option (Right to Buy) | |
Kimberly J. Manhard | Executive VP, Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.80 per share. | 24 Apr 2017 | 5,250 | 5,250 (0%) | 0% | 8.8 | 46,200 | Common Stock |